Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study

The shot combined with a Merck immunotherapy reduced the risk of relapse in people with skin cancer in a study, Moderna said.

The Wall Street Journal | I+D | Salud |

Leer noticia completa en el medio original
Spanish